psoriasis
Conditions
Interventions
Group 1 :7.5 mg/week
Group 2:10 mg/week
Group 3:15 mg/week
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The age of the patient is 18-65 years old, and the gender is not limited; 2. Patients with confirmed moderate to severe psoriasis: disease duration >= 6 months, BSA >= 5% and PASI >= 5% at screening; 3. Have not received systemic treatment (Acitretin, cyclosporine, ultraviolet phototherapy, MTX, etc.) in the past 1 month, and have not received external drug treatment (vitamin D3 derivatives, retinoic acid, glucocorticoids, etc.) in the past 2 weeks hormones, calcineurin inhibitors, etc.), and the investigator believes that the patient is suitable for treatment; 4. Patients voluntarily sign informed consent and can be followed up on schedule.
Exclusion criteria
Exclusion criteria: 1. The patient has other active skin diseases that may affect the evaluation of the condition; 2. Patients who have received MTX treatment in the past and are clearly intolerant or ineffective to MTX; 3. Abnormal laboratory tests: at the time of screening, hemoglobin (Hb) was less than 80% of the lower limit of normal. The peripheral blood white blood cell count is less than 4.0 x 10^9/L, or greater than 12 x 10^9/L. The neutrophil count in peripheral blood was less than 1.5 x 10^9/L. Platelets are less than the lower limit of normal. Liver function (any one of ALT and TBIL) > 2 times the upper limit of normal value; if there is any abnormality, a re-examination is allowed. Renal function (serum creatinine Scr) > 2 times the upper limit of normal; 4. Suffering from serious, progressive, uncontrolled diseases of important organs and systems (including cardiovascular, liver, lung, and kidney), other autoimmune diseases, malignant tumors, and combined with other diseases that are considered inappropriate by the investigators Other diseases participating in this study; 5. Have a history of severe allergic reactions; 6. Received systemic treatment within 1 month before screening; received external drug treatment within 2 weeks before screening; 7. Women who are pregnant, breastfeeding and plan to become pregnant within one year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriatic lesion area;Psoriatic Lesion Severity Index; | — |
Countries
China
Contacts
Public ContactJiajing Lu
Shanghai Skin Disease Hospital
Outcome results
None listed